Abstract:Significance Immune activation and inflammation are predictors of serious non-AIDS events even in virally suppressed HIV-1−infected individuals. This does not apply to HIV-2−infected patients, who experience a form of attenuated HIV-1 disease. Here, we show that the HIV-1 matrix protein 17 (p17) binds to and activates the common beta chain receptor (βCR). The βCR-activating epitope on p17 is expressed on the matrix protein of HIV-1 ancestors but not on that of HIV-2 and its ancestors. Our finding highlights this epitope as a signature tracing the HIV-1 evolutionary trajectory that may have represented a critical step to enhance the HIV-1 ancestors aggressiveness and early human-to-human transmission. Whether this functional epitope actually marks the pathogenic difference between HIV-1 and HIV-2 needs further investigation. The HIV-1 matrix protein p17 (p17) is a pleiotropic molecule impacting on different cell types. Its interaction with many cellular proteins underlines the importance of the viral protein as a major determinant of human specific adaptation. We previously showed the proangiogenic capability of p17. Here, by integrating functional analysis and receptor binding, we identify a functional epitope that displays molecular mimicry with human erythropoietin (EPO) and promotes angiogenesis through common beta chain receptor (βCR) activation. The functional EPO-like epitope was found to be present in the matrix protein of HIV-1 ancestors SIV originated in chimpanzees (SIVcpz) and gorillas (SIVgor) but not in that of HIV-2 and its ancestor SIVsmm from sooty mangabeys. According to biological data, evolution of the EPO-like epitope showed a clear differentiation between HIV-1/SIVcpz-gor and HIV-2/SIVsmm branches, thus highlighting this epitope on p17 as a divergent signature discriminating HIV-1 and HIV-2 ancestors. P17 is known to enhance HIV-1 replication. Similarly to other βCR ligands, p17 is capable of attracting and activating HIV-1 target cells and promoting a proinflammatory microenvironment. Thus, it is tempting to speculate that acquisition of an epitope on the matrix proteins of HIV-1 ancestors capable of triggering βCR may have represented a critical step to enhance viral aggressiveness and early human-to-human SIVcpz/gor dissemination. The hypothesis that the p17/βCR interaction and βCR abnormal stimulation may also play a role in sustaining chronic activation and inflammation, thus marking the difference between HIV-1 and HIV-2 in term of pathogenicity, needs further investigation.

Identification of amino acid residues critical for the B cell growth-promoting activity of HIV-1 matrix protein p17 variants.

Molecular Mechanisms Involved in the B Cell Growth and Clonogenic Activity of HIV-1 Matrix Protein p17 Variants

A Single Amino Acid Substitution Confers B-cell Clonogenic Activity to the HIV-1 Matrix Protein P17

Role of HIV-1 Matrix Protein P17 Variants in Lymphoma Pathogenesis

F-103 A Conformational Switch That Turns on the B Cell Growth- Promoting Activity of the HIV-1 Matrix Protein P17

Molecular mechanisms behind the generation of pro-oncogenic HIV-1 matrix protein p17 variants

Evolution Toward Beta Common Chain Receptor Usage Links the Matrix Proteins of HIV-1 and Its Ancestors to Human Erythropoietin.

P-D11 Effect of HIV-1 matrix protein p17 on natural killer cell mediated antibody-dependent cellular cytotoxicity

Angiogenic, lymphangiogenic and adipogenic effects of HIV-1 matrix protein p17.

The Hiv-1 Matrix Protein P17 Activates the Transcription Factors C-Myc and Creb in Human B Cells

Cellular Aspartyl Proteases Promote the Unconventional Secretion of Biologically Active HIV-1 Matrix Protein P17

HIV-1 matrix protein p17 and its variants promote human triple negative breast cancer cell aggressiveness

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

High Expression of HIV-1 Matrix Protein P17 in Both Lymphoma and Lymph Node Tissues of AIDS Patients.

Identification of a Clade-Specific HLA-C*03:02 CTL Epitope GY9 Derived from the HIV-1 p17 Matrix Protein

Identification of Novel Key Amino Acids at the Interface of the Transmembrane Domains of Human BST-2 and HIV-1 Vpu.

Hydrophobic Mutations In Buried Polar Residues Enhance Hiv-1 Gp41 N-Terminal Heptad Repeat-C-Terminal Heptad Repeat Interactions And C-Peptides' Anti-Hiv Activity

A longitudinal analysis of immune escapes from HLA-B*13-restricted T-cell responses at early stage of CRF01_AE subtype HIV-1 infection and implications for vaccine design

Amino acid substitution of the membrane-proximal external region alter neutralization sensitivity in a chronic HIV-1 clade B infected patient

Polymorphic residues in HLA-B that mediate HIV control distinctly modulate peptide interactions with both TCR and KIR molecules